Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments

被引：0

作者：

Nieto Barbero, Ma Asuncion ^{[1
]}

Javier Gonzalez-Gamiz, Francisco ^{[1
]}

Jesus Rodriguez-Nieto, Ma ^{[2
]}

Sanchez, Susana ^{[3
]}

Gaudo, Javier ^{[4
]}

Valenzuela, Claudia ^{[5
]}

Lopez-Muniz, Belen ^{[6
]}

Gomez-Carrera, Luis ^{[7
]}

Laporta, Rosalia ^{[8
]}

Casanova, Alvaro ^{[9
]}

Teresa Rio, Maria ^{[10
]}

Neumomadrid, Refipimad ^{[11
]}

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] Fdn Jimenez Diaz, Madrid, Spain

[3] Hosp Univ Principe de Asturias, Alcaa De Henares, Spain

[4] Hosp Univ Ramon y Cajal, Madrid, Spain

[5] Hosp Univ Princesa, Madrid, Spain

[6] Hosp Univ Infanta Leonor, Madrid, Spain

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Puerta de Hierro, Majadahonda, Spain

[9] Hosp Univ Henares, Coslada, Spain

[10] Hosp Univ Getafe, Getafe, Spain

[11] Neumomadrid, Madrid, Spain

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

Idiopathic pulmonary fibrosis; Treatments; Comorbidities;

D O I：

10.1183/13993003.congress-2019.PA1301

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA1301

引用

页数：3

共 50 条

[1] Adherence and Persistence to Antifibrotic Treatments for Idiopathic Pulmonary Fibrosis
Raimundo, Karina
Kong, Amanda
Gray, Stephani
Benloucif, Slim
Limb, Susan
CHEST, 2017, 152 (04) : 441A - 441A
[2] Efficacy of Antifibrotic Treatments for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Sugino, K.
Ono, H.
Watanabe, N.
Ando, M.
Tsuboi, E.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
[3] The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
Kette, Stefano
Reccardini, Nicolo
Salton, Francesco
Confalonieri, Paola
Andrisano, Alessia
Chianese, Maria
De Nes, Anna
Maggisano, Marta
Galantino, Alessandra
Nicolosi, Salvatore
Mari, Marco
Salotti, Andrea
Angoni, Darina
Chernovsky, Maria
Hughes, Michael
Confalonieri, Marco
Mondini, Lucrezia
Ruaro, Barbara
PHARMACEUTICALS, 2025, 18 (03)
[4] Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments Focus on Experimental Studies
Lunardi, Francesca
Pezzuto, Federica
Vuljan, Stefania Edith
Calabrese, Fiorella
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (09) : 1090 - 1097
[5] Antifibrotic choice in idiopathic pulmonary fibrosis
Hayton, Conal
Morris, Helen
Marshall, Tracey
Zakis, Katie
Garfoot, Theresa
Ortega, Pilar Rivera
Greaves, Melanie
Leonard, Colm
Chaudhuri, Nazia
EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[6] Antifibrotic treatment of idiopathic pulmonary fibrosis
Markart, P.
Drakopanagiotakis, F.
Wygrecka, M.
PNEUMOLOGE, 2020, 17 (03): : 177 - 185
[7] Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Ehlers-Tenenbaum, Svenja
Oltmanns, Ute
Palmowski, Karin
Muley, Thomas
Schaaf, Miriam
Warth, Arne
Schnabel, Philipp A.
Heussel, Claus P.
Herth, Felix J. F.
Kreuter, Michael
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[8] Antifibrotic therapy for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Teoh, A.
Glenn, L.
Corte, T.
Holland, A.
RESPIROLOGY, 2023, 28 : 202 - 202
[9] Comorbidities in Idiopathic Pulmonary Fibrosis
Mendes de Moraes, F. G.
Anselmo, F.
Faria, L. F.
Lopes, M. C.
Rangel, B.
Bessa, E.
Rufino, R.
Costa, C. H.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[10] Treatments And Outcomes Of Idiopathic Pulmonary Fibrosis In A Medicare Population Prior To Approval Of Antifibrotic Therapies
Mooney, J.
Chang, E.
Lalla, D.
Papoyan, E.
Raimundo, K.
Reddy, S. R.
Stauffer, J. L.
Yan, J. T.
Broder, M. S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195

← 1 2 3 4 5 →